UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported) March 13, 2015
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware	000-20852	16-1387013
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2000 Technology Parkway, Newark, New York			14513
(Address of principal executive offices)			(Zip Code)
(315) 332-7100
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

As previously disclosed, on April 28, 2014 Ultralife Corporation’s Board of Directors approved a share repurchase program that became effective on May 1, 2014. On March 13, 2015, the Company adopted a written trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934, as amended. The Company may utilize this plan to make purchases of its common stock through April 30, 2015, the expiration date of its share repurchase program, and covering a period during which it would otherwise be subject to a self-imposed trading blackout. Repurchases under the previously announced repurchase plan and the trading plan are subject to the Securities and Exchange Commission’s regulations as well as certain price, market, volume and timing constraints specified in the plans.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	ULTRALIFE CORPORATION
March 16, 2015	By:	/s/ Philip A. Fain
		Chief Financial Officer and Treasurer